Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 94.49% | 551.44% | |||
| Total Other Revenue | 27,677.78% | -- | |||
| Total Revenue | 108.04% | 551.76% | |||
| Cost of Revenue | 67.09% | 275.51% | |||
| Gross Profit | 110.45% | 581.28% | |||
| SG&A Expenses | 53.29% | 28.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 59.03% | 21.84% | |||
| Operating Income | 41.98% | 54.47% | |||
| Income Before Tax | 35.21% | 40.17% | |||
| Income Tax Expenses | -102.89% | 3,208.40% | |||
| Earnings from Continuing Operations | 51.76% | 21.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.76% | 21.26% | |||
| EBIT | 41.98% | 54.47% | |||
| EBITDA | 42.81% | 54.82% | |||
| EPS Basic | 52.89% | 22.61% | |||
| Normalized Basic EPS | 38.30% | 41.18% | |||
| EPS Diluted | 56.38% | 16.43% | |||
| Normalized Diluted EPS | 38.30% | 41.18% | |||
| Average Basic Shares Outstanding | 2.43% | 1.74% | |||
| Average Diluted Shares Outstanding | 2.43% | 1.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||